Is It Time for a More Holistic Approach to the Treatment of Multiple Myeloma?

IF 0.9 Q4 HEMATOLOGY Hemato Pub Date : 2021-10-01 DOI:10.3390/hemato2040040
F. Sharpley, Hannah Miller, R. Spencer, Dane Bradwell, Janet Parkinson, Yvette Ibbotson, S. Jowitt
{"title":"Is It Time for a More Holistic Approach to the Treatment of Multiple Myeloma?","authors":"F. Sharpley, Hannah Miller, R. Spencer, Dane Bradwell, Janet Parkinson, Yvette Ibbotson, S. Jowitt","doi":"10.3390/hemato2040040","DOIUrl":null,"url":null,"abstract":"In the UK, approximately 5820 new cases of multiple myeloma (MM) are diagnosed each year. This number has increased by a third since the early 1990s. Considerable progress has been achieved in our ability to treat MM as a result of the development of new chemotherapeutic agents. MM is a disease more commonly seen in elderly individuals who frequently have pre-existing co-morbidities and are subject to social pressures that impact adversely on their quality of life (QOL). As their lives are extended by more effective treatment of MM, there is a greater need to address such issues. This review will focus on the holistic needs of a patient with MM, and how all members of the multidisciplinary team have a role. The aim is to advocate for centres to support MM patients to live well with their condition.","PeriodicalId":93705,"journal":{"name":"Hemato","volume":" ","pages":""},"PeriodicalIF":0.9000,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hemato","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/hemato2040040","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

In the UK, approximately 5820 new cases of multiple myeloma (MM) are diagnosed each year. This number has increased by a third since the early 1990s. Considerable progress has been achieved in our ability to treat MM as a result of the development of new chemotherapeutic agents. MM is a disease more commonly seen in elderly individuals who frequently have pre-existing co-morbidities and are subject to social pressures that impact adversely on their quality of life (QOL). As their lives are extended by more effective treatment of MM, there is a greater need to address such issues. This review will focus on the holistic needs of a patient with MM, and how all members of the multidisciplinary team have a role. The aim is to advocate for centres to support MM patients to live well with their condition.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
是时候采取更全面的方法治疗多发性骨髓瘤了吗?
在英国,每年大约有5820例新的多发性骨髓瘤(MM)被诊断出来。自20世纪90年代初以来,这一数字增加了三分之一。由于新的化疗药物的开发,我们治疗MM的能力取得了相当大的进展。MM是一种常见于老年人的疾病,他们经常存在并存疾病,并受到社会压力的影响,对他们的生活质量(QOL)产生不利影响。由于更有效的MM治疗延长了他们的生命,因此更需要解决这些问题。本综述将着重于MM患者的整体需求,以及多学科团队的所有成员如何发挥作用。目的是倡导中心支持MM患者与他们的病情生活得很好。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.30
自引率
0.00%
发文量
0
审稿时长
11 weeks
期刊最新文献
The Novel Anti-Cancer Agent, SpiD3, Is Cytotoxic in CLL Cells Resistant to Ibrutinib or Venetoclax. Synthetic Lethality Approaches in Acute Lymphoblastic Leukemia Hemato Keeps You Updated on the Research in Hematology The Role of Platelet Molecules in Risk Stratification of Patients with COVID-19 Fibril-Forming Organelles in Mesangial Cells in Renal Biopsies from Patients with Light-Chain-Associated Amyloidosis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1